Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Apr 13, 2026
TickeronGET DAILY SIGNALS
Why Is Replimune Group (REPL) Stock Down -63.24% Today?

Why Is Replimune Group (REPL) Stock Down -63.24% Today?

Key Takeaways

  • Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75.
  • The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
  • Replimune's CEO confirmed the company will cut its workforce and substantially scale back U.S. manufacturing operations as a direct consequence.
  • Management stated that without timely accelerated FDA approval, continued development of RP1 is not viable — effectively placing the company's lead asset in jeopardy.
  • A wave of analyst downgrades swept across Wall Street over the weekend, with price targets slashed to between $1 and $4.
  • Investors are now closely watching whether Replimune will pursue another regulatory submission, seek a Type A meeting with the FDA, or pivot to other pipeline assets.

Opening Summary

Replimune Group, Inc. (REPL) is a Woburn, Massachusetts-based clinical-stage biotechnology company that develops oncolytic immunotherapies — treatments that use genetically modified viruses to selectively attack cancer cells and stimulate the immune system. Shares of REPL entered Monday's premarket session in freefall, trading near $1.75 as of the early hours of April 13, 2026, compared to Friday's closing price of $4.76 — a decline of approximately 63.24%. The immediate trigger was the U.S. Food and Drug Administration's decision, disclosed after Friday's market close, to again refuse approval of Replimune's lead drug candidate RP1 for the treatment of advanced melanoma, marking the second such rejection in less than a year.

FDA's Second Complete Response Letter

On April 10, 2026 — the PDUFA target action date — the FDA issued a second Complete Response Letter for Replimune's BLA seeking accelerated approval of RP1 in combination with Bristol Myers Squibb's nivolumab (Opdivo) for patients with advanced melanoma who had progressed on anti-PD-1-based therapy. The FDA's reviewers from the Office of Therapeutic Products and the Oncology Center of Excellence unanimously determined that the data presented were "insufficient to conclude substantial evidence of effectiveness." The agency maintained its earlier objection that the pivotal IGNYTE trial — a single-arm study showing a 34% response rate and a median duration of response of 24.8 months — does not qualify as an adequate and well-controlled clinical investigation, and that the heterogeneity of the patient population makes results difficult to interpret.

Replimune resubmitted the application in October 2025 following the first rejection in July 2025, including new analyses on RP1's mechanism of action and additional data. However, the FDA affirmed its prior position, expanding upon original concerns rather than softening them. CEO Sushil Patel expressed surprise at the outcome, noting the issues outlined in the CRL had not been raised during mid- and late-cycle reviews, and that the company believed it had aligned with the FDA on confirmatory study design.

Operational Fallout: Layoffs and Manufacturing Cutbacks

The consequences of the second rejection extend well beyond the stock price. CEO Sushil Patel announced that Replimune is compelled to reduce its workforce and significantly downsize its U.S. manufacturing operations as a direct result of the FDA's decision. The company had previously warned in a February 2026 SEC filing that a second CRL could lead management to determine that RP1's development is "no longer viable." Without timely accelerated approval, Replimune has stated publicly that advancing RP1 for advanced cancer patients with few treatment alternatives will not be feasible.

Cascade of Analyst Downgrades

The FDA's decision triggered an unusually broad and severe round of analyst downgrades over the weekend, compounding the selling pressure entering Monday's premarket:

  • Jefferies downgraded REPL to Hold from Buy and slashed its price target to $2 from $13, calling the road ahead "tough."
  • JPMorgan downgraded to Underweight from Neutral, withdrawing its prior $10 price target entirely, and warned shares would likely trade in the low single digits amid "greater uncertainty on the prospects for RP1."
  • BMO Capital Markets downgraded to Underperform with a $1 price target, down from $11.
  • Cantor Fitzgerald cut to Neutral from Overweight, noting the FDA reaffirmed and expanded upon its prior concerns, rather than offering more regulatory flexibility.
  • Piper Sandler lowered its rating to Neutral and reduced its price target to $4 from $14.
  • H.C. Wainwright issued a double downgrade to Sell from Buy, citing the need to await clarity on any regulatory path forward.

Market Context and Trading Activity

The premarket decline in REPL was accompanied by sharply elevated trading volume relative to normal pre-market activity, consistent with forced institutional repositioning following the Friday-night announcement. The stock had already lost approximately 19–20% during regular Friday trading as the CRL news broke, and the after-hours and premarket sessions extended the selloff dramatically as analysts and funds absorbed the full implications overnight. A NASDAQ volatility trading halt was triggered during Friday's session as prices moved sharply.

The broader biotech sector, tracked by the SPDR S&P Biotech ETF (XBI), was not under comparable pressure, underscoring that this was a company-specific and binary-event-driven move rather than a systemic sector rotation. The collapse also reflects the market pricing in an existential threat to Replimune's core pipeline, given that RP1 represented the company's singular near-term commercial opportunity with potential peak annual sales of up to $800 million according to prior analyst estimates.

Trending AI Robots

For traders navigating volatile, catalyst-driven events like the REPL FDA-driven collapse, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing automated trading strategies under current market conditions. Tickeron operates hundreds of AI-powered trading bots covering thousands of tickers across equities, ETFs, and other instruments — but only the top performers, ranked by real-time metrics including return, win rate, and risk-adjusted performance, are featured in this dedicated section. Bots vary by strategy type (momentum, mean-reversion, breakout), timeframe (intraday to swing), and the symbols they trade, giving investors a range of approaches to explore. Explore the Trending AI Robots page to identify AI-driven strategies aligned with your trading style and current market environment.

What Comes Next for REPL

Replimune has indicated it plans to request a Type A meeting with the FDA — typically granted within 30 days — to understand whether any regulatory path to accelerated approval for RP1 remains open. The company is also conducting the Phase 3 IGNYTE-3 confirmatory trial, and earlier data in acral melanoma may provide an alternative submission basis. However, with management explicitly warning that RP1 development is not viable without accelerated approval, the timeline to any potential resubmission remains deeply uncertain. Investors will be watching for announcements regarding the Type A meeting outcome, any strategic partnership or licensing discussions, the scope of the workforce reduction, and whether Replimune revisits early-stage pipeline assets including RP2 and RP3 as potential go-forward programs. Cash runway and financing capacity will also be key concerns given the company's pre-revenue clinical-stage status and the sharp reduction in market capitalization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: REPL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


REPL in -10.05% downward trend, declining for three consecutive days on November 17, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where REPL declined for three days, in 259 of 307 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for REPL moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 69 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 178 of 218 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.596). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of oncolytic immunotherapies

Industry Biotechnology

Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
465
Web
https://www.replimune.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.